By Barbara Obstoj-Cardwell. Editor
Johnson & Johnson has agreed to pay $30 billion in cash for Actelion, and will not even get the whole drugs pipeline. Actelion shareholders should bite J&J’s arm off, according to the Financial Times’ Lex column.
This deal has the untidy look that can result from late concessions by an overly eager bidder when a rival acquirer is hovering. Founder and chief executive officer Jean-Paul Clozel will sail off into the sunset across Lake Lucerne helming a biotech comprising Actelion’s prospective and early stage treatments
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze